RNLXY on OTC

Renalytix plc

Renalytix plc is a British medical laboratories services company based in London.2 Its shares trade on OTC under the symbol RNLXY.2

Price unavailable

Last updated Oct 20, 2026.

Overview

$2.3MRevenue, fiscal 20243
-$33.5MNet income, fiscal 20243

Compare with BioNexus Gene Lab Corp, YD Bio Ltd or Psychemedics Corporation, or pick any stock.

  • TickerRNLXY on OTC2
  • IndustryServices-Medical Laboratories2
  • HeadquartersLondon, United Kingdom2
  • Incorporated inUnited Kingdom4
  • Business addressFinsgate, 5-7 Cranwood Street, London4
  • Filer category, Emerging growth company4
  • Legal formPublic Limited Company2
  • LEI213800NTOH3FK3WER5512
  • StatusActive2
  • LEI statusIssued and current2
  • Registered address2 LEMAN STREET, E1W 9US London, United Kingdom2
  • Registered withCompanies House, 112576552

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

6.8%Gross margin3
-1293.5%Operating margin3
-1461.6%Net margin3
2189.0%Revenue growth, 20243

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue93¢$2.1M
  • Other costs7¢$152.0K
  • Income tax0¢$4.0K

Out of $2.3M in revenue.3 The company lost money this year.

Financial statements

Revenue673$2.3M in 2024
0$1.0M$2.0M$3.0M2020: $0$020202021: $1.5M$1.5M20212022: $3.0M$3.0M2022+99%2023: $100.0K$100.0K2023−97%2024: $2.3M$2.3M2024+2189%
Gross profit673$156.0K in 2024
0$250.0K$500.0K$750.0K$1.0M2020: $0$020202021: $633.0K$633.0K20212022: $874.0K$874.0K2022+38%2023: $720.0K$720.0K2023−18%2024: $156.0K$156.0K2024−78%
Operating income8673-$29.6M in 2024−30% since 2019
-$60.0M-$40.0M-$20.0M02019: -$42.3M-$42.3M20192020: -$10.3M-$10.3M2020−76%2021: -$31.9M-$31.9M2021+209%2022: -$53.2M-$53.2M2022+67%2023: -$42.2M-$42.2M2023−21%2024: -$29.6M-$29.6M2024−30%
Net income8673-$33.5M in 2024−21% since 2019
-$60.0M-$40.0M-$20.0M02019: -$42.3M-$42.3M20192020: -$9.8M-$9.8M2020−77%2021: -$35.3M-$35.3M2021+259%2022: -$45.3M-$45.3M2022+28%2023: -$45.6M-$45.6M2023+1%2024: -$33.5M-$33.5M2024−27%
Fiscal year2018201920202021202220232024
Revenue$06$1.5M6$3.0M7$100.0K7$2.3M3
Cost of revenue$06$858.0K6$2.1M7$2.7M3$2.1M3
Gross profit$06$633.0K6$874.0K7$720.0K3$156.0K3
Operating expenses$54.1M7$42.9M3$29.8M3
Operating income-$42.3M8-$10.3M6-$31.9M6-$53.2M7-$42.2M3-$29.6M3
Income before tax-$45.3M7-$45.6M3-$33.5M3
Income tax$06$06$25.0K7$2.0K3$4.0K3
Net income-$42.3M8-$9.8M6-$35.3M6-$45.3M7-$45.6M3-$33.5M3
Earnings per share-$0.176-$0.496-$0.627-$0.553-$0.313
Earnings per share (diluted)-$0.176-$0.496-$0.677-$0.553-$0.313
Shares (weighted, basic)72.9M shares782.2M shares3108.2M shares3
Shares (weighted, diluted)73.8M shares782.2M shares3108.2M shares3

Compare Renalytix plc with another company

Corporate structure

Renalytix plc sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Renalytix plc

  • JEFFERSON RIVER CAPITAL LLC Filed SCHEDULE 13D/A on Renalytix plc, latest Feb 23, 2026 (5 filings since Feb 17, 2023)
  • UBS Filed SCHEDULE 13G/A on Renalytix plc, latest Apr 30, 2025 (3 filings since Feb 10, 2025)
  • CVI Investments, Inc. Filed SC 13G/A on Renalytix plc, latest Nov 14, 2024 (2 filings since Apr 4, 2024)
  • School Of Medicine At Mount Sinai Icahn Filed SC 13D/A on Renalytix plc, latest Nov 5, 2024 (5 filings since May 27, 2022)
  • GILDER GAGNON HOWE & CO LLC Filed SC 13G/A on Renalytix plc, latest Feb 14, 2023 (3 filings since Feb 11, 2022)
  • Renalytix plc London, United Kingdom
    • Renalytix AI Limited Subsidiary · Ireland

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Renalytix plc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$1.5M3 Jun 30, 2024$1.5M3 Jun 30, 2023+0.1%
Property and equipment, before depreciation$515.0K3 Jun 30, 2024$1.9M3 Jun 30, 2023−72.6%
Accumulated depreciation$299.0K3 Jun 30, 2024$850.0K3 Jun 30, 2023−64.8%
Property and equipment, net$216.0K3 Jun 30, 2024$1.0M3 Jun 30, 2023−79.0%
Operating-lease assets (leased space)$03 Jun 30, 2024$159.0K3 Jun 30, 2023−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.7M3 Jun 30, 2024$24.7M3 Jun 30, 2023−81.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$869.0K3 Jun 30, 2024$1.1M3 Jun 30, 2023−17.2%
Finite-lived intangibles, gross$1.5M7 Jun 30, 2023$1.5M7 Jun 30, 2022+3.4%
Accumulated amortization$658.0K3 Jun 30, 2024$476.0K3 Jun 30, 2023+38.2%
Finite-lived intangibles, net$869.0K3 Jun 30, 2024$1.1M7 Jun 30, 2023−17.2%

Leadership

Who has led Renalytix plc, and when. Pick a name to see everywhere that person has worked.

President

  1. Thomas H. McLain2023

Chief financial officer

  1. O. James Sterling2023
  2. Joel R. Jung2024
2025
Board members and other officers (9)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Renalytix AI Limited Ireland5

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Renalytix AI plcMay 15, 2020 to Jun 25, 20214

Timeline

  1. Jan 16, 20258-K Regulation FD disclosure26
  2. Dec 20, 20248-K Shareholder vote; Regulation FD disclosure27
  3. Nov 19, 20248-K Entered a material agreement; New debt or obligation28
  4. Nov 6, 20248-K Executive or director change; Shareholder vote; Regulation FD disclosure29
  5. Oct 1, 20248-K Entered a material agreement; Completed an acquisition or sale; Results of operations30
  6. Aug 27, 20248-K Listing notice or transfer; Regulation FD disclosure31
  7. Jul 15, 20248-K Unregistered sale of shares; Regulation FD disclosure32
  8. Jun 25, 20248-K Change of auditor33
  9. Jun 24, 20248-K Change of auditor34
  10. Jun 24, 20248-K Listing notice or transfer35
  11. Jun 17, 20248-K Regulation FD disclosure36
  12. Jun 12, 20248-K Executive or director change37
  13. Mar 15, 2018Founded Renalytix plc is founded2

Calendar

When it reported results

  1. Oct 1, 2024Reported quarterly or annual results30
  2. May 15, 2024Reported quarterly or annual results38
  3. Feb 15, 2024Reported quarterly or annual results39
  4. Nov 14, 2023Reported quarterly or annual results40
  5. Sep 28, 2023Reported quarterly or annual results41

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

199 filings to the SEC since October 2021: 7 annual reports, 4 quarterly reports, 45 major events, 29 insider forms, 18 large holders, 96 other. The latest 20:

  1. Feb 23, 2026SCHEDULE 13D/A EDGAR
  2. Jul 30, 2025EFFECT EDGAR
  3. Jul 30, 2025EFFECT EDGAR
  4. Jul 30, 2025EFFECT EDGAR
  5. Jul 30, 2025EFFECT EDGAR
  6. Jul 30, 2025EFFECT EDGAR
  7. Jul 30, 202515-12G EDGAR
  8. Jul 30, 2025424B3 EDGAR
  9. Jul 29, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
  10. Jul 29, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
  11. Jul 29, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
  12. Jul 29, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-3 ON FORM S-3 EDGAR
  13. Jul 29, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-3 ON FORM S-3 EDGAR
  14. Jul 25, 2025S-8 POS REGISTRATION STATEMENT EDGAR
  15. Jul 25, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
  16. Apr 30, 2025SCHEDULE 13G/A EDGAR
  17. Apr 30, 2025SCHEDULE 13G/A EDGAR
  18. Feb 10, 2025SCHEDULE 13G EDGAR
  19. Jan 16, 20258-K CURRENT REPORT EDGAR
  20. Dec 20, 20248-K CURRENT REPORT EDGAR

The 199 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024James McCullough56$509.6K$780.1K47
2024Thomas McLain$420.6K$761.7K47
2024O. James Sterling$345.4K$467.2K47
2024Fergus Fleming57$310.5K$425.7K47
2024Michael J. Donovan70$328.4K$380.0K47
2023Chief Executive Officer and Director$601.3K$1.0M47
2023Prior President$450.3K$662.7K47
2023Prior Chief Financial Officer$426.3K$623.7K47

SEC filer profile

How Renalytix plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRenalytix plc1
  • CIK0001811115
  • Filer status<br>emerging growth company1
  • Incorporated inUnited Kingdom1
  • Fiscal year endsJune 301
  • Industry code (SIC)8071 Services-Medical Laboratories1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business addressFinsgate, 5-7 Cranwood Street, London, United Kingdom1
  • Phone44 29 2071 05701
  • Shares outstanding331,206,012 as of Nov 7, 202411
  • Public float$24.7M as of Dec 29, 20233
  • On EDGAR sinceMay 15, 20201
  • Filings233 in all: 8-K (43), 6-K (37), 4 (15), EFFECT (15), 3 (14), CORRESP (12), UPLOAD (9), POS AM (8)1
    All 49 form types

    424B3 (6), SC 13D/A (5), 10-Q (4), DEF 14A (4), PRE 14A (4), SC 13G/A (4), 20-F (3), 20-F/A (3), S-3 (3), SC 13G (3), 10-K (2), 424B5 (2), 8-K/A (2), F-3 (2), F-6 POS (2), S-3/A (2), S-8 (2), S-8 POS (2), SC 13D (2), SCHEDULE 13G/A (2), 10-K/A (1), 15-12G (1), 25 (1), 424B4 (1), 6-K/A (1), 8-A12B (1), ARS (1), CERT (1), DEFA14A (1), DEFR14A (1), DRS (1), F-1 (1), F-1/A (1), F-6 (1), F-6/A (1), FWP (1), NT 10-Q (1), RW (1), RW WD (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Sep 30, 2024
    Quarterly report (10-Q) Nov 19, 2024
    Proxy statement (DEF 14A) Nov 25, 2024
    Latest 8-K (8-K) Jan 16, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47